中南大学李乾斌

Central South University|

+

个人信息

李乾斌

教授

教授博士生导师

入职时间：2010-04-22

所在单位：湘雅药学院

职务：博士生导师

学历：博士研究生毕业

办公地点：湖南省长沙市岳麓区桐梓坡路172号中南大学湘雅药学院

在职信息：在职

同专业博导

同专业硕导

论文成果

当前位置: 中文主页 >> 论文成果

Guo Y., Cao M., Li Z., Zhou H., Chen Z., Li Q. Discovery of a novel 2,4-thiazolidinedione derivative as dual inhibitor of beta-catenin/TCF4 interaction and tubulin polymerization in colon cancer cells. Arch Pharm (Weinheim), 2025, 358(3): e2400796.
Hu X., Wu Y., Yao M., Chen Z., Li Q. The other side of the coin: protein deubiquitination by Ubiquitin-Specific Protease 1 in cancer progression and therapy. Future Med. Chem., 2025, 17(3): 329-345.
Hu Y., Wang Y., Tan W., Zhao C., Li M., Xiang S., Liang X., Gao R., Zeng B., Chen Z., Hu L., Li Q. Design and Optimization of LOXL2 and sGC Dual-Target Regulators Targeting Extracellular Matrix Dysregulation and Vasodilation for the Treatment of Pulmonary Arterial Hypertension. J Med Chem, 2025.
Le X., Chen Q., Cao S., Hu G., Li Q., Chen Z. Pan-Cdk inhibitor ZK304709 suppresses Cdc20 expression and potentiates the anticancer activity of apcin in HeLa cervical cancer cells. Acta. Pharm., 2025.
Le X., Chen Q., Wen Q., Cao S., Zhang L., Hu L., Hu G., Li Q., Chen Z. Design, synthesis and optimization of Apcin analogues as Cdc20 inhibitors for triple-negative breast cancer therapy. Eur J Med Chem, 2025, 289: 117434.
Tan W., Wang Y., Li M., Zhao C., Hu Y., Gao R., Chen Z., Hu L., Li Q. A novel pyridine-2-one AMPK inhibitor: Discovery, mechanism, and in vivo evaluation in a hypoxic pulmonary arterial hypertension rat model. Eur J Med Chem, 2025, 286: 117266.
Wei J., Feng W., Chen Q., Li Q., Chen Z. Rational discovery of molecular glue degraders based on block chemistry. Drug Discov Today, 2025, 30(11): 104480.
Wu Y., Hu X., Wang S., Ouyang H., Yao M., Chen Z., Li Q. Fragment-based discovery, dynamics simulation and pharmacological study of 2-amino-pyrimidine derivative as HIPK2 inhibitor. Chem. Biol. Interact., 2025, 421: 111771.
Zhao R., Zhao C., Gao R., Cai Q., Li Q., Hu L. Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics. Drug Discov Today, 2025, 30(1): 104287.
Hu X., Wang S., Fu S., Zeng J., Wu Y., Gong L., Cao Y., Zhang Y., Han Y., Ouyang H., Xiong Y., He X., Cheng J., Zou S., Chen Z., Tao L., Meng J., Huang L., Yuan Q., Peng Z., Li Q. Discovery of XRF-1021, a 2,4-disubstituted-5-fluoropyrimidine derivative as a homeodomain-interacting protein kinase 2 inhibitor for the treatment of chronic kidney disease. Eur J Med Chem, 2026, 302(Pt 2): 118353.
Yao M., Wu Y., Hu X., Feng C., Xu J., Chen Z., Li Q. Design, synthesis, and in vitro anti-renal fibrotic effects of imidazopyridazine-based homeodomain-interacting protein kinase 2 inhibitors. Bioorg Med Chem, 2026, 132: 118456.
Li, Q., Xu, W. Novel anticancer targets and drug discovery in post genomic age. Curr. Med. Chem. Anticancer Agents 2005, 5(1): 53-63.
Xu, W., Li, Q. Progress in the development of aminopeptidase N (APN/CD13) inhibitors. Curr. Med. Chem. Anticancer Agents 2005, 5(3): 281-301.
Li, Q., Fang, H., Xu, W. Novel 3-galloylamido-N'-substituted-2,6 -piperidinedione-N-acetamide peptidomimetics as metalloproteinase inhibitors. Bioorg. Med. Chem. Lett. 2007, 17(10): 2935-2938.
Li, Q., Al-Ayoubi, A., Guo, T., Zheng, H., Sarkar, A., Nguyen, T., Eblen, S.T., Grant, S., Kellogg, G.E., Zhang, S. Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors. Bioorg. Med. Chem. Lett. 2009, 19(21): 6042-6046.
Li, Q., Fang, H., Wang, X., Hu, L., Xu, W. Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Design, chemistry and activity evaluation. Part I. Eur. J. Med. Chem. 2009, 44(12): 4819-4825.
Li, Q., Fang, H., Wang, X., Xu, W. Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. Structure-based design, chemistry and activity evaluation. II. Eur. J. Med. Chem. 2010, 45(4): 1618-1626.
Li, Q., Wu, J., Zheng, H., Liu, K., Guo, T.L., Liu, Y., Eblen, S.T., Grant, S., Zhang, S. Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine -2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways. Bioorg. Med. Chem. Lett. 2010, 20(15): 4526-4530.
Li, Q., Fang, H., Wang, X., Hu, G., Wang, Q., Xu, W. Novel potent 2,5-pyrrolidinedione peptidomimetics as aminopeptidase N inhibitors. Design, synthesis and activity evaluation. Bioorg. Med. Chem. Lett. 2012, 22(2): 850-853.
Lv, M., Chen, Z., Hu, G., Li, Q. Therapeutic strategies of diabetic nephropathy: recent progress and future perspectives. Drug Discov. Today 2015, 20(3): 332-346.

共68条 3/4

首页上页下页尾页页